Mr. Chair, our intent with the new cost recovery regime--as I said, we hope to begin consultations next month--is to bring additional resources into our regulatory system. So in that respect it's very important for us. The User Fees Act requires that we establish service standards for each of the fees that we propose. In some areas that's quite easy to do, and in others it's much more complicated. I'll give you two examples.
We do inspections of manufacturing sites. That's fairly easy to measure; it's a certain amount of activity. In an area like that, we think it's likely to do full cost recovery. In post-market surveillance--looking at adverse drug reaction reports, that kind of thing--it's much more difficult to identify the receiver of the service. In many ways it's the Canadian public. So we're going to have to establish and propose what the right balance is in each area of our activity. I expect we'll end up with a mix of fees that really reflects the balance of public and private interest--100% in some, and much lower in others.